Filtered By:
Drug: Vytorin

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 235 results found since Jan 2013.

Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention 　- A Meta-Analysis of 12 Randomized Trials.
CONCLUSIONS: In secondary prevention patients, the relative benefits of high-dose statin, ezetimibe-statin, and PCSK9 inhibitor-statin treatments were varied and decreased gradually, of which high-dose statin was significantly superior to PCSK9 inhibitor-statin for improving MACE and revascularization per 1 mmol/L reduction of LDL-C. PMID: 31006730 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 18, 2019 Category: Cardiology Authors: Wang S, Xiu J, Liao W, Liao Y, Bin J Tags: Circ J Source Type: research

Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade?
We describe the current status of lipid-lowering therapies for ischemic stroke prevention. The SPARCL trial published in 2006 has been a landmark study in vascular neurology. The trial demonstrated that high-dose atorvastatin prevents recurrent stroke, and led the AHA/ASA to recommend statin therapy for patients with stroke or TIA of atherosclerotic origin.Recent findingsRecently, the J-STARS study demonstrated that therapy with low-dose pravastatin reduced atherothrombotic infarction incidence among patients with prior ischemic stroke. Besides, several trials have shown improved stroke outcomes with non-statin lipid-lower...
Source: Current Treatment Options in Neurology - April 7, 2019 Category: Neurology Source Type: research

A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus.
CONCLUSIONS: Statin-ezetimibe co-therapy is found more efficacious than statin monotherapy in reducing the incidence of CVD with no significant difference between diabetic and non-diabetic individuals. PMID: 30915779 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - March 28, 2019 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage – A Meta-Analysis
Background: The association of lipid lowering therapy and intracerebral hemorrhage risk is controversial. Methods: We performed a cumulative meta-analysis of lipid lowering trials that reported intracerebral hemorrhage. Statin, fibrate, ezetimibe, PCSK9, and CETP trials were included. We explored whether the association of lipid lowering therapy and risk of intracerebral hemorrhage may vary by baseline low-density lipoprotein (LDL) level, mean change in LDL or baseline cardiovascular risk of population.
Source: Journal of Stroke and Cerebrovascular Diseases - March 12, 2019 Category: Neurology Authors: Conor Judge, Sarah Ruttledge, Maria Costello, Robert Murphy, Elaine Loughlin, Alberto Alvarez-Iglesias, John Ferguson, Sarah Gorey, Aoife Nolan, Michelle Canavan, Martin O'Halloran, Martin J. O'Donnell Source Type: research

A Review of the 2018 Cholesterol Guidelines: Focus on Nonstatin Lipid-lowering Drugs
The 2018 Cholesterol Clinical Practice Guidelines were released and endorsed by multiple associations including the National Lipid Association, American Diabetes Association, American Pharmacists Association, American Society for Preventive Cardiology, and Preventive Cardiovascular Nurses Association, to name a few.1 Since the prior guideline and addendums, studies have been published showing the benefit of nonstatin lipid-lowering agents. Ezetimibe demonstrated atherosclerotic cardiovascular disease (ASCVD) morbidity reduction (specifically myocardial infarction and stroke) in patients with acute coronary syndrome when ad...
Source: The Journal for Nurse Practitioners - January 3, 2019 Category: Nursing Authors: Roda Plakogiannis Tags: Prescription Pad Source Type: research

Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.
Conclusion: The price of alirocumab would have to be reduced considerably to be cost-effective. Because substantial reductions already have occurred, we believe that timely, independent cost-effectiveness analyses can inform clinical and policy discussions of new drugs as they enter the market. Primary Funding Source: University of California, San Francisco, and Institute for Clinical and Economic Review. PMID: 30597485 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - January 1, 2019 Category: Internal Medicine Authors: Kazi DS, Penko J, Coxson PG, Guzman D, Wei PC, Bibbins-Domingo K Tags: Ann Intern Med Source Type: research

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
CONCLUSIONS: Moderate- to high-quality evidence suggests that ezetimibe has modest beneficial effects on the risk of CVD endpoints, primarily driven by a reduction in non-fatal MI and non-fatal stroke, but it has little or no effect on clinical fatal endpoints. The cardiovascular benefit of ezetimibe might involve the reduction of LDL-C, total cholesterol and triglycerides. There is insufficient evidence to determine whether ezetimibe increases the risk of adverse events due to the low and very low quality of the evidence. The evidence for beneficial effects was mainly obtained from individuals with established atheroscler...
Source: Cochrane Database of Systematic Reviews - November 19, 2018 Category: General Medicine Authors: Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X Tags: Cochrane Database Syst Rev Source Type: research

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, Eugene BraunwaldSummaryBackgroundPolyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute corona...
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research

Is very low LDL-C harmful?
CONCLUSION: Achieving an LDL-C of 40-50 mg/dl seems to be safe, and importantly might offer CV beneficial effects. Data for attaining levels below 25 mg/dl is limited, however in favor of such reductions. PMID: 30295187 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 8, 2018 Category: Drugs & Pharmacology Authors: Faselis C, Imprialos K, Grassos H, Pittaras A, Kallistratos M, Manolis A Tags: Curr Pharm Des Source Type: research

Lipids: a personal view of the past decade.
Authors: Katsiki N, Mikhailidis DP Abstract The past decade has witnessed considerable progress in the field of lipids. New drugs have been "rapidly" developed and some of these drugs have already been evaluated in event-based large trials. This evidence has led to the guidelines recommending new, more aggressive treatment goals for low-density lipoprotein cholesterol (LDL-C) levels. Although LDL-C remains the principal goal for cardiovascular disease (CVD) risk reduction, there has also been considerable interest in other lipid variables, such as high-density lipoprotein cholesterol, triglycerides, and lipoprotein...
Source: Hormones - September 21, 2018 Category: Endocrinology Tags: Hormones (Athens) Source Type: research

The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia.
Abstract Statins, 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors, have been used for decades for the prevention of coronary artery disease and stroke. They act primarily by lowering serum cholesterol through the inhibition of cholesterol synthesis in the liver, which results in the upregulation of low-density lipoprotein receptors in the liver. This results in the removal of low-density lipoprotein-cholesterol. Studies have suggested that statins may demonstrate additional effects that are independent of their effects on low-density lipoprotein-cholesterol. These have been termed "pleiotropic" effects. P...
Source: Current Vascular Pharmacology - August 17, 2018 Category: Drugs & Pharmacology Authors: Liao JK, Oesterle A Tags: Curr Vasc Pharmacol Source Type: research

Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain
ConclusionsTreatment with evolocumab is associated with a lower frequency of cardiovascular events, but is inefficient for patients suitable to receive this drug in the Spanish National Health System.ResumenIntroducción y objetivosAnalizar la razón de coste-efectividad y el impacto presupuestario del tratamiento con evolocumab (inhibidor de la PCSK9) para pacientes en prevención secundaria en el Sistema Nacional de Salud español.MétodosSe realizaron, desde la perspectiva del sistema sanitario público, análisis de impacto presupuestario, modelos de árbol de decisión y Markov, basándose en el único ensayo clínico...
Source: Revista Espanola de Cardiologia - July 10, 2018 Category: Cardiology Source Type: research

Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
PMID: 29891625 [PubMed - in process]
Source: Circulation - June 12, 2018 Category: Cardiology Authors: Bohula EA, Wiviott SD, Giugliano RP, Park JG, Murphy SA, Cannon CP, Braunwald E Tags: Circulation Source Type: research